Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17373963 | 0.96 | VCAM1 (0.38) | KMT2AMEN1VCAM1MAPTALDH1A1 | |
| SCHEMBL1998098 | 0.91 | KMT2A (0.44) | KMT2AMEN1KDM4E | |
| SCHEMBL28506184 | 0.89 | ALOX15 (0.46) | KMT2AMEN1MAPTKDM4ELMNA | |
| SCHEMBL23813735 | 0.88 | PAOX (0.41) | KMT2AMEN1VCAM1MAPTALDH1A1 | |
| SCHEMBL27050874 | 0.88 | VCAM1 (0.46) | KMT2AVCAM1MAPTALDH1A1HTT | |
| SCHEMBL27050860 | 0.88 | VCAM1 (0.46) | KMT2AVCAM1MAPTALDH1A1HTT | |
| SCHEMBL15236082 | 0.88 | DGKA (0.46) | KMT2ATSHRMAPTLMNAMAPK1 | |
| SCHEMBL27239124 | 0.88 | DGKA (0.46) | KMT2ATSHRMAPTLMNAMAPK1 | |
| SCHEMBL2000685 | 0.86 | ALOX15 (0.41) | KMT2AMAPTALDH1A1HTTKDM4E | |
| SCHEMBL19402698 | 0.86 | VCAM1 (0.43) | KMT2AMEN1VCAM1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2025-02-27 | — | — | US | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| WO-2024220546-A2 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND METHODS OF USE AND SYNTHETIC PROCESSES AND INTERMEDIATES | PEAK BIO, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-117653740-A | Antibody drug conjugates for ablating hematopoietic stem cells | 诺华股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110099697-B | Antibody drug conjugates for ablating hematopoietic stem cells | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| US-20220305134-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-09-29 | — | — | US | disclosed |
| WO-2018116178-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2018-06-28 | — | — | WO | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| EP-3215519-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | Novartis AG (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-3154997-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | Novartis AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| WO-2016071856-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015189791-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | ABL1, BCR, CD47 | KMT2A 28/4885MEN1 1822/4885VCAM1 230/4885 |
| US-20220305134-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | KMT2A 21/4885MEN1 2274/4885VCAM1 253/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | KMT2A 1486/4885MEN1 4413/4885VCAM1 758/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | KMT2A 2505/4885MEN1 1913/4885VCAM1 1894/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | KMT2A 3167/4885MEN1 986/4885VCAM1 258/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | KMT2A 4406/4885MEN1 687/4885VCAM1 78/4885 |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | BCR, ABL1, CD47 | KMT2A 21/4885MEN1 2274/4885VCAM1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.